TY - JOUR
T1 - New GOLD classification :
T2 - Longitudinal data on group assignment
AU - Casanova, Ciro
AU - Martinez-Gonzalez, Cristina
AU - de Lucas-Ramos, Pilar
AU - Mir-Viladrich, Isabel
AU - Cosio, Borja
AU - Peces-Barba, German
AU - Calle-Rubio, Miryam
AU - Solanes García, Ingrid
AU - Agüero, Ramón
AU - de Diego-Damia, Alfredo
AU - Feu-Collado, Núria
AU - Irigaray, Rosa
AU - Balcells, Eva
AU - Llunell, Antònia
AU - Galdiz, Juan Bautista
AU - Marín, Margarita
AU - Soler Cataluña, Juan José
AU - Lopez-Campos, José Luis
AU - Soriano, Joan B.
AU - de-Torres, Juan P.
AU - Calvo Bonachera, José
AU - Lacárcel Bautista, Celia
AU - Domenech, Adolfo
AU - Michavila, Inmaculada Alfageme
AU - Marín Trigo, José María
AU - González, C.M.
AU - Piqueras, B.G.C.
AU - Cabrera-Lopez, Carlos
AU - Sánchez Acosta, Alejandro
AU - Abreu González, Juan
AU - Miguel Campos, Elena
AU - Marín, Alicia
AU - Moreno, Amalia
AU - Márquez Pérez, Francisca Lourdes
AU - Riesco Miranda, Juan Antonio
AU - Rodríguez, Julia Tabara
AU - Golpe, Rafael
AU - de Miguel Díez, Javier
AU - García Río, Francisco
AU - Díaz Lobato, Salvador
PY - 2014
Y1 - 2014
N2 - Rationale: Little is known about the longitudinal changes associated with using the 2013 update of the multidimensional GOLD strategy for chronic obstructive pulmonary disease (COPD).Objective: To determine the COPD patient distribution of the new GOLD proposal and evaluate how this classification changes over one year compared with the previous GOLD staging based on spirometry only.Methods: We analyzed data from the CHAIN study, a multicenter observational Spanish cohort of COPD patients who are monitored annually. Categories were defined according to the proposed GOLD: FEV%, mMRC dyspnea, COPD Assessment Test (CAT), Clinical COPD Questionnaire (CCQ), and exacerbations-hospitalizations. One-year follow-up information was available for all variables except CCQ data.Results: At baseline, 828 stable COPD patients were evaluated. On the basis of mMRC dyspnea versus CAT, the patients were distributed as follows: 38.2% vs. 27.2% in group A, 17.6% vs. 28.3% in group B, 15.8% vs. 12.9% in group C, and 28.4% vs. 31.6% in group D. Information was available for 526 patients at one year: 64.2% of patients remained in the same group but groups C and D show different degrees of variability. The annual progression by group was mainly associated with one-year changes in CAT scores (RR, 1.138; 95%CI: 1.074-1.206) and BODE index values (RR, 2.012; 95%CI: 1.487-2.722).Conclusions: In the new GOLD grading classification, the type of tool used to determine the level of symptoms can substantially alter the group assignment. A change in category after one year was associated with longitudinal changes in the CAT and BODE index. © 2014 Casanova et al.; licensee BioMed Central Ltd.
AB - Rationale: Little is known about the longitudinal changes associated with using the 2013 update of the multidimensional GOLD strategy for chronic obstructive pulmonary disease (COPD).Objective: To determine the COPD patient distribution of the new GOLD proposal and evaluate how this classification changes over one year compared with the previous GOLD staging based on spirometry only.Methods: We analyzed data from the CHAIN study, a multicenter observational Spanish cohort of COPD patients who are monitored annually. Categories were defined according to the proposed GOLD: FEV%, mMRC dyspnea, COPD Assessment Test (CAT), Clinical COPD Questionnaire (CCQ), and exacerbations-hospitalizations. One-year follow-up information was available for all variables except CCQ data.Results: At baseline, 828 stable COPD patients were evaluated. On the basis of mMRC dyspnea versus CAT, the patients were distributed as follows: 38.2% vs. 27.2% in group A, 17.6% vs. 28.3% in group B, 15.8% vs. 12.9% in group C, and 28.4% vs. 31.6% in group D. Information was available for 526 patients at one year: 64.2% of patients remained in the same group but groups C and D show different degrees of variability. The annual progression by group was mainly associated with one-year changes in CAT scores (RR, 1.138; 95%CI: 1.074-1.206) and BODE index values (RR, 2.012; 95%CI: 1.487-2.722).Conclusions: In the new GOLD grading classification, the type of tool used to determine the level of symptoms can substantially alter the group assignment. A change in category after one year was associated with longitudinal changes in the CAT and BODE index. © 2014 Casanova et al.; licensee BioMed Central Ltd.
KW - COPD
KW - GOLD
KW - Longitudinal
U2 - 10.1186/1465-9921-15-3
DO - 10.1186/1465-9921-15-3
M3 - Article
C2 - 24417879
SN - 1465-9921
VL - 15
JO - Respiratory Research
JF - Respiratory Research
IS - 1
ER -